American Society of Retina Specialists Artificial Intelligence Task Force Report.

Autor: Talcott KE; Center for Ophthalmic Bioinformatics, Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.; Cleveland Clinic Lerner College of Medicine, Cleveland, OH, USA., Baxter SL; Division of Ophthalmology Informatics and Data Science, Viterbi Family Department of Ophthalmology and Shiley Eye Institute, University of California San Diego, La Jolla, CA, USA.; Division of Biomedical Informatics, Department of Medicine, University of California San Diego, La Jolla, CA, USA., Chen DK; Department of Ophthalmology, NYU Grossman School of Medicine, New York University, NY, USA.; Genentech/Roche, South San Francisco, CA, USA., Korot E; Retina Specialists of Michigan, Grand Rapids, MI, USA.; Horngren Family Vitreoretinal Center, Byers Eye Institute, Department of Ophthalmology, Stanford University School of Medicine, Palo Alto, CA, USA., Lee A; Roger and Angie Karalis Johnson Retina Center, Department of Ophthalmology, School of Medicine, University of Washington, Seattle, WA, USA., Kim JE; Department of Ophthalmology and Visual Sciences, Medical College of Wisconsin, Milwaukee, WI, USA., Modi Y; Department of Ophthalmology, NYU Grossman School of Medicine, New York University, NY, USA., Moshfeghi DM; Horngren Family Vitreoretinal Center, Byers Eye Institute, Department of Ophthalmology, Stanford University School of Medicine, Palo Alto, CA, USA., Singh RP; Center for Ophthalmic Bioinformatics, Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.; Cleveland Clinic Lerner College of Medicine, Cleveland, OH, USA.; Cleveland Clinic Martin Health, Stuart, FL, USA.
Jazyk: angličtina
Zdroj: Journal of vitreoretinal diseases [J Vitreoretin Dis] 2024 Apr 20; Vol. 8 (4), pp. 373-380. Date of Electronic Publication: 2024 Apr 20 (Print Publication: 2024).
DOI: 10.1177/24741264241247602
Abstrakt: Since the Artificial Intelligence Committee of the American Society of Retina Specialists developed the initial task force report in 2020, the artificial intelligence (AI) field has seen further adoption of US Food and Drug Administration-approved AI platforms and significant development of AI for various retinal conditions. With expansion of this technology comes further areas of challenges, including the data sources used in AI, the democracy of AI, commercialization, bias, and the need for provider education on the technology of AI. The overall focus of this committee report is to explore these recent issues as they relate to the continued development of AI and its integration into ophthalmology and retinal practice.
Competing Interests: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Dr. Talcott reports personal fees from Genentech/Roche, Apellis, and EyePoint and research fees from Zeiss and RegenxBio. Dr. Baxter reports personal fees from voxelcloud.io and equipment support from Optomed and Topcon. Dr. Chen is a Genentech employee. Dr. Korot reports personal fees from Alimera and Topcon, being an owner of Sanro, and being a previous employee of Genentech/Roche. Dr. Lee reports grants from Santen, personal fees from Genentech, personal fees from the US Food and Drug Administration, grants from Carl Zeiss Meditec, personal fees from Gyroscope, nonfinancial support from Microsoft Corp, and grants from Regeneron. Dr. Kim reports personal fees from Allergan, Apellis, Bausch + Lomb, Clearside Biomedical, DORC, Genentech/Roche, Novartis, Notal Vision, and Outlook Therapeutics, Regeneron. Dr. Modi reports personal fees from Alimera, Allergan, Zeiss, DORC, Genentech, Iveric Bio, and Thea Pharma. Dr. Moshfeghi reports personal fees from Akebia, Alcon, Allegro, Congruence, DSentz, Inc, Genentech, Linc, Novartis, Pykus, and Regeneron. Dr. Singh reports personal fees from Genentech/Roche, Alcon, Novartis, Regeneron, Asclepix, Gyroscope, Bausch + Lomb, and Apellis.
(© The Author(s) 2024.)
Databáze: MEDLINE